

P. Nolan

Page 1 of 5
RECEIVED

AUG 15 2000

ENTERED

TECH CENTER 1644 1600/2900

P#14

RAW SEQUENCE LISTING

DATE: 07/26/2000

PATENT APPLICATION: US/09/031,629A

TIME: 12:28:17

Input Set : A:\Sequence.lst

Output Set: N:\CRF3\07262000\I031629A.raw

C--> 3 <110> APPLICANT: Faustman
4 Hayashi
6 <120> TITLE OF INVENTION: Methods for Treating and Diagnosing Autoimmune Disease
8 <130> FILE REFERENCE: MGH/Faustman 17633/1030
15 <140> CURRENT APPLICATION NUMBER: 09/031,629A
16 <141> CURRENT FILING DATE: 1998-02-21
18 <160> NUMBER OF SEQ ID NOS: 6
20 <170> SOFTWARE: PatentIn Ver. 2.1
22 <210> SEQ ID NO: 1
23 <211> LENGTH: 4
24 <212> TYPE: PRT
25 <213> ORGANISM: Artificial Sequence
27 <220> FEATURE:
28 <223> OTHER INFORMATION: Description of Artificial Sequence: Fluorogenic
29 peptide used for degradation assays
31 <220> FEATURE:
32 <221> NAME/KEY: SITE
33 <222> LOCATION: (4)
34 <223> OTHER INFORMATION: 7-amino-4-methylcoumarin is attached to the
35 C-terminal Tyr
37 <220> FEATURE:
38 <221> NAME/KEY: SITE
39 <222> LOCATION: (1)
40 <223> OTHER INFORMATION: The N-terminal Leu contains a succinyl
41 modification
43 <400> SEQUENCE: 1
44 Leu Leu Val Tyr
45 1
48 <210> SEQ ID NO: 2
49 <211> LENGTH: 3
50 <212> TYPE: PRT
51 <213> ORGANISM: Artificial Sequence
53 <220> FEATURE:
54 <223> OTHER INFORMATION: Description of Artificial Sequence: Fluorogenic
55 peptide used for degradation assays
57 <220> FEATURE:
58 <221> NAME/KEY: SITE
59 <222> LOCATION: (3)
60 <223> OTHER INFORMATION: 7-amido-4-methylcoumarin is attached to the
61 C-terminal Arg
63 <220> FEATURE:
64 <221> NAME/KEY: SITE
65 <222> LOCATION: (1)
66 <223> OTHER INFORMATION: The N-terminal Leu contains a tert-butyloxycarbonyl
67 modification
69 <400> SEQUENCE: 2
70 Leu Arg Arg

RECEIVED

AUG 15 2003

TECH CENTER 1600/2900

RAW SEQUENCE LISTING DATE: 07/26/2000
 PATENT APPLICATION: US/09/031,629A TIME: 12:28:17

Input Set : A:\Sequence.lst
 Output Set: N:\CRF3\07262000\I031629A.raw

```

71 1
74 <210> SEQ ID NO: 3
75 <211> LENGTH: 3
76 <212> TYPE: PRT ✓
77 <213> ORGANISM: Artificial Sequence ✓
79 <220> FEATURE:
80 <223> OTHER INFORMATION: Description of Artificial Sequence: Fluorogenic ✓
81 peptide used for degradation assays
83 <220> FEATURE:
84 <221> NAME/KEY: SITE
85 <222> LOCATION: (3)
86 <223> OTHER INFORMATION: beta-naphthylamide is attached to the C-terminal
87 Glu
89 <220> FEATURE:
90 <221> NAME/KEY: SITE
91 <222> LOCATION: (1)
92 <223> OTHER INFORMATION: The N-terminal Leu contains a carbenzoyx
93 modification
95 <400> SEQUENCE: 3
96 Leu Leu Glu
97 1
100 <210> SEQ ID NO: 4
101 <211> LENGTH: 6
102 <212> TYPE: PRT ✓
103 <213> ORGANISM: Artificial Sequence ✓
105 <220> FEATURE:
106 <223> OTHER INFORMATION: Description of Artificial Sequence: Heptapeptide ✓
107 from the carboxy-terminal domain of RNA polymerase
108 II large subunit
110 <400> SEQUENCE: 4
111 Tyr Ser Pro Thr Pro Ser
112 1 5
115 <210> SEQ ID NO: 5
116 <211> LENGTH: 32 ✓
117 <212> TYPE: DNA ✓
118 <213> ORGANISM: Artificial Sequence ✓
120 <220> FEATURE:
121 <223> OTHER INFORMATION: Description of Artificial Sequence: Probe for ✓
122 wild-type kappa B1 sequence
124 <400> SEQUENCE: 5
125 gatctaggga ctttcgctg gggactttcc ag 32
128 <210> SEQ ID NO: 6
129 <211> LENGTH: 40 ✓
130 <212> TYPE: DNA ✓
131 <213> ORGANISM: Artificial Sequence ✓
133 <220> FEATURE:
134 <223> OTHER INFORMATION: Description of Artificial Sequence: Probe for ✓
135 wild-type kappa B2 sequence
137 <400> SEQUENCE: 6

```

RECEIVED

AUG 15 2003

TECH CENTER 1600/2200

RAW SEQUENCE LISTING DATE: 07/26/2000
PATENT APPLICATION: US/09/031,629A TIME: 12:28:17

Input Set : A:\Sequence.lst
Output Set: N:\CRF3\07262000\I031629A.raw

138 gatctcaggg gaatctccct ctccttttat gggcgtagcg 40

VERIFICATION SUMMARY DATE: 07/26/2000
PATENT APPLICATION: US/09/031,629A TIME: 12:28:18

Input Set : A:\Sequence.lst
Output Set: N:\CRF3\07262000\I031629A.raw

L:16 M:271 C: Current Filing Date differs, Replaced Current Filing Date